Crowdonomics
All companies
FluidForm Bio, Inc. logo

FluidForm Bio, Inc.

Operating

Biotech · Waltham, MA

Latest valuation
—
No round has disclosed a priced valuation or cap.
Total raised
$15,303,790
Crowd $0 · Private $15.3M · 4 rounds since 2023
Latest share price
$0.0969
Section 4(a)(2) · Series Seed Plus Preferred Stock · Jun 2024 offering price · down round

Financials

FY2023–FY2024 · from SEC filings · hover any figure for its source
$1.9M
−$5.5M
2023
$169K
−$4.4M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2023 reviewed
FY2024 reviewed
Income statement
Revenue
$1,948,705
$168,783
Cost of goods sold
$34,036
$24,150
Gross margin
98%
86%
Net income
-$5,528,532
-$4,391,085
Taxes paid
$0
$0
Balance sheet
Cash
$550,105
$960,117
Accounts receivable
$21,300
$65,209
Total assets
$3,711,506
$1,550,829
Short-term debt
$1,464,686
$1,077,554
Long-term debt
$2,206,635
$121,897
Total liabilities
$3,671,321
$1,199,451
Other
Headcount
—
11

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Share price over rounds

log scale
$0.8109$0.2803$0.0969
Aug 2023Jun 2024
Round offering price or verified disclosed saleDisclosed sale, unverified or year-onlyDown round · Jun 2024 (-88.1%)

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Share counts as of Dec 31, 2024
Common Stock · 3.01%Series Seed Plus Preferred Stock · 97.0%
ClassOutstandingVotes / shareShare of totalLast price
Common Stock1,440,376—3.01%—
Series Seed Plus Preferred Stockpreferred46,370,382—97.0%$0.0969Jun 2024
Total47,810,758100%

Shares outstanding over timein today's share terms

46M23M0
Dec 2023Dec 2024
Common StockSeries Seed Plus Preferred StockRound opened

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Team

3 people
Michael Graffeo
Chief Executive Officer, Chairman of the Board
Adam Feinberg
Chief Technology Officer, Board Member
Erik Waters
Chief Financial Officer

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not obligated

never closed a Reg CF raise

20 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form DAug 27, 20260001123292-26-001178
    EDGAR
  • Form C-UJul 3, 20250001665160-25-001270
    EDGAR
  • Form CApr 2, 20250001665160-25-000511
    EDGAR
Source: SEC EDGARCIK 0002062460DEShare price $0.0969Last synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.